Latest filing published 01 Sept 2021 for Pieris Pharmaceuticals, INC., €49k.
Insider track record
Not enough buy signals with a settled T+90 horizon to measure a track record yet.
No signal scores available.
Shane Olwill: trading record in brief
Shane Olwill, listed as senior executive, appears in our data through filings on Palvella Therapeutics, Inc. shares, published by SEC (Form 4). Altogether 3 filings, all relating to 30 August 2021.
The open-market record consists of 2 sales worth €166k, with no purchase. Besides market trades, the filings include 1 option exercise.
The record was last updated on 1 September 2021 with an open-market sale (€39k) in Palvella Therapeutics, Inc. Typically, a trade is published a median of 2 days after it takes place. For comparison, the SEC allows two business days to file a Form 4. A sale on its own says little: insiders also sell to pay tax, fund a purchase or diversify. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.
Companies and markets linked to Shane Olwill
Open company profiles for insider transactions, fundamentals and analyst consensus when available.
- 38,400 shares@ US$1.52100.0% of flowCommon StockSEC:0001562180-21-005712:0
1 of 1 declaration
